COVID-19 implicated in conjunctivitis
May 15, 2020
The COVID-19 virus can cause ocular complications such as conjunctivitis, though not necessarily in the early stages of the disease, according to researchers.
Laird Harrison
Visual impairment high among Rohingya refugees
May 7, 2020
Rohingya refugees are three- to six-times more likely to be blind than the native Bangladeshi population, but there are replicable, low-cost models for provide effective eye care in crisis settings, a new study by the NGO Orbis Internatio
Genetic analysis could predict myopia in children
May 1, 2020
Clinicians may soon be able to use genetic information alone to determine the risk of myopia in very young children, according to researchers.
Genetics analysis may predict myopia in children
April 15, 2020
Clinicians may soon be able to use genetic information alone to determine the risk of myopia in very young children, researchers believe.
Preservative-free tafluprost/timolol lowers IOP well, glaucoma study shows
April 7, 2020
A fixed-dose tafluprost and timolol combination eye drop led to significant reductions in intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) and ocular hypertension (OHT) in a safety a
Ranibizumab reported safe for bilateral macular degeneration
April 2, 2020
Clinicians may safely use ranibizumab 0.5 mg in patients with bilateral age-related macular degeneration (AMD) as well as those with best-corrected visual acuity (BCVA) of less than 2/10, an Italian real-life study suggests.
Surgical iridotomy safer than YAG in younger uveitis patients
April 1, 2020
A retrospective study concludes that surgical peripheral iridotomy (PI) has several advantages over laser treatment in some patients with uveitis.
New model predicts retinopathy of prematurity based on birth characteristics
March 11, 2020
A model based on simple birth characteristics may provide a new, more efficient method for predicting the need for retinopathy of prematurity treatment in infants, according to researchers.
Topical DME drug shows promise in Phase II trial
March 10, 2020
A novel eyedrop formulation of dexamethasone was found to reduce swelling and improve vision in a Phase II trial of patients with diabetic macular oedema (DME).
Light-adjustable IOL technology creates novel treatment window
October 28, 2019
This article was reviewed by David Chang, MD
